The startup develops biotherapeutics that target unique sugar and lipid signatures on viruses and cancers, which are absent in normal cells and not subject to mutation. Their lead product, VTRU200, provides an alternative treatment for drug-resistant cancers and infectious diseases that traditional protein-targeting therapies cannot effectively address.
Funding
$300K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer and infectious disease treatments target proteins, which are prone to mutation and downregulation, leading to drug resistance. Traditional therapies struggle to address these evolving targets effectively.
Solution
This startup develops biotherapeutics that target unique sugar and lipid signatures present on viruses and cancers but absent in normal cells. These signatures are not encoded by mRNA and are less susceptible to mutation, offering a more stable therapeutic target. Their lead product, VTRU200, provides an alternative treatment approach for drug-resistant cancers and infectious diseases that traditional protein-targeting therapies cannot effectively address. By focusing on these invariant signatures, the company aims to overcome the limitations of current treatments and improve patient outcomes.
Target Audience
The primary target audience includes patients with drug-resistant cancers and infectious diseases, as well as oncologists and infectious disease specialists seeking alternative treatment options.
Features
- VTRU200 targets aberrant sugar and lipid signatures on viruses and cancers.
- Signatures are not present on normal cells, minimizing off-target effects.
- Targets are not encoded by mRNA, reducing the likelihood of resistance development.
- Designed to address drug-resistant cancers and infectious diseases.